$31.82+1.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 3, 2026
Just reported
From IDEAYA Biosciences, Inc.'s results release of November 3, 2026; its quarterly report has since been filed.
Actual
$10.2M
-95% y/y
+16% q/q
Guided
—
No guide given
Actual
-$1.22
Guided
—
No guide given
Actual
-$137.6M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $10.2M | $207.8M | -95.07% |
| Profit | -$125.7M | $119.2M | -205.46% |
| Profit per share | -$1.22 | $1.33 | -191.73% |
| Free Cash Flow | -$93.8M | $142.2M | -165.94% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
IDEAYA Biosciences, Inc. reported on November 3, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We are encouraged by the continued momentum at IDEAYA during the third quarter, marked by the successful completion of our first NDA filing for darovasertib in metastatic uveal melanoma,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small-molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from IDEAYA Biosciences, Inc.’s Item 2.02 8-K filed November 3, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.